| Description | Naxitamab (Hu3F8) is a humanized monoclonal antibody against GD2 (hu3F8). Naxitamab has antitumor activity and can be used to study neuroblastoma, osteosarcoma, and other GD2-positive cancers. |
| In vitro | Naxitamab（Hu3F8；72小时）对神经毛细胞瘤细胞系LAN-1显示出细胞毒性作用，其半数有效浓度（EC50）值为5.1 μg/mL[1]。在周围血单个核细胞（PBMC）和多形核白细胞（PMN）存在的条件下，Naxitamab (0.1-1 μg/mL；4小时) 展示了依赖抗体的细胞介导的细胞毒作用（ADCC）[1]。 |
| In vivo | 在裸鼠携带LAN-1异种移植瘤模型中，Naxitamab（Hu3F8；100 mg/kg；静脉注射；每周两次，持续4周）可抑制神经母细胞瘤异种移植瘤的生长[1]。 |
| Target activity | LAN1:5.1 μg/mL |
| Synonyms | Naxitamab-gqgk, Humanized 3F8, Hu3F8 |
| molecular weight | N/A |
| CAS | 1879925-92-4 |
| Storage | store at low temperature | store at -80°C |
| References | 1. Cheung NK, et, al. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology. 2012 Jul 1;1(4):477-486. |